About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Denver | 15,604 Studies Near You | Clareo Health

Clinical Trials LocationsDenver

Clinical Trials in Denver

Discover 15,604 clinical trials near Denver, Colorado. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3261-3280 of 15,604 trials

COMPLETEDPhase 4< 1 mile

Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"

NCT05528653

To evaluate if utilizing Telehealth medicine for access to HIV PrEP will engage more Black and Latino Men who have sex with Men (MSM)

Vivent Health75 participantsStarted Jul 2022

Denver, Colorado, United States • St Louis, Missouri, United States • Milwaukee, Wisconsin, United States

COMPLETEDPhase 1/2< 1 mile

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

NCT03425279

The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.

Undifferentiated Pleomorphic SarcomaMyxofibrosarcoma

BioAtla, Inc.245 participantsStarted Feb 2018

Tucson, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +37 more locations

Find Trials by Condition in Denver

Breast Cancerin Denver Lung Cancerin Denver Prostate Cancerin Denver Colorectal Cancerin Denver Melanomain Denver Leukemiain Denver Lymphomain Denver Pancreatic Cancerin Denver Ovarian Cancerin Denver Brain Cancerin Denver Diabetesin Denver

Data from ClinicalTrials.govTerms

RECRUITINGPhase 1< 1 mile

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432

This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will also evaluate RLY-2608 in combination RLY-2608 + fulvestrant and in triple combination RLY-2608 + fulvestrant + CDK4/6 inhibitor (palbociclib or ribociclib) or CDK4 inhibitor (PF-07220060) for patients with HR+ HER2- locally advanced or metastatic breast cancer. The RLY-2608 single agent arm, RLY-2608 + fulvestrant combination arm, and triple combination arms will have 2 parts: a dose escalation (Part 1) and a dose expansion (Part 2).

PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+4 more

Relay Therapeutics, Inc.930 participantsStarted Dec 2021

Tucson, Arizona, United States • San Diego, California, United States • Denver, Colorado, United States +34 more locations

COMPLETED< 1 mile

EchoTip AcuCore Post-Market Clinical Study

NCT06358001

The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.

AdenocarcinomaNeuroendocrine TumorsHepatocellular Carcinoma+5 more

Cook Research Incorporated183 participantsStarted Aug 2024

Orange, California, United States • Denver, Colorado, United States • Gainesville, Florida, United States +5 more locations

RECRUITINGPhase 28.4 miles

TArgeting Type 1 Diabetes Using POLyamines (TADPOL)

NCT05594563

The goal of this clinical trial is to test a drug known as DFMO in people with Type 1 Diabetes (T1D). The main question\[s\] it aims to answer are: * Does it reduce stress on the cells that make insulin? * Does it preserve what is left of the body's insulin production? Participants will take either DFMO or a placebo (looks like DFMO but has no active ingredients) two times a day for about 6 months. Participants will have 6 in person visits and 1 phone visit over a period of 12 months. Visits will include blood draws urine collection and other tests.

Type 1 Diabetes

Emily K. Sims70 participantsStarted Mar 2023

Aurora, Colorado, United States • Chicago, Illinois, United States • Indianapolis, Indiana, United States +4 more locations

Active Not RecruitingPhase 3334 miles

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

NCT01503632

This randomized phase III trial studies compliance to a mercaptopurine treatment intervention compared to standard of care in younger patients with acute lymphoblastic leukemia that has had a decrease in or disappearance of signs and symptoms of cancer (remission). Assessing ways to help patients who have acute lymphoblastic leukemia to take their medications as prescribed may help them in taking their medications more consistently and may improve treatment outcomes.

Acute Lymphoblastic Leukemia

Children's Oncology Group570 participantsStarted Feb 2012

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Downey, California, United States +99 more locations

Active Not RecruitingPhase 2498 miles

Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

NCT06033833

This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks. The number of visits will be 18.

Sanofi335 participantsStarted Sep 2023

Stockton, California, United States • Boynton Beach, Florida, United States • Miami, Florida, United States +65 more locations

Active Not RecruitingPhase 3501 miles

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

NCT05456425

The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.

Cloudbreak Therapeutics, LLC660 participantsStarted Jun 2022

Dothan, Alabama, United States • Sun City, Arizona, United States • Bakersfield, California, United States +41 more locations

Active Not RecruitingPhase 3501 miles

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577

The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.

Merck Sharp & Dohme LLC1,089 participantsStarted Jul 2023

Springdale, Arkansas, United States • Los Angeles, California, United States • San Francisco, California, United States +162 more locations

COMPLETEDPhase 3558 miles

A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

NCT05425056

The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an arteriovenous fistula for hemodialysis vascular access.

Complication of Renal DialysisEnd Stage Renal DiseaseEnd Stage Kidney Disease+5 more

Vascular Therapies, Inc.136 participantsStarted Aug 2022

San Diego, California, United States • Torrance, California, United States • Washington D.C., District of Columbia, United States +19 more locations

RECRUITING576 miles

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

NCT06279572

This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.

Acute Myeloid Leukemia

Mayo Clinic80 participantsStarted Apr 2021

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States

COMPLETEDPhase 2605 miles

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

NCT04340362

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

Glomerulosclerosis, Focal Segmental

Vertex Pharmaceuticals Incorporated16 participantsStarted Jun 2020

Birmingham, Alabama, United States • San Diego, California, United States • Washington D.C., District of Columbia, United States +41 more locations

COMPLETEDPhase 2699 miles

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

NCT05907291

The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of atumelnant (CRN04894) in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals Inc.38 participantsStarted Jul 2023

Pasadena, California, United States • Ann Arbor, Michigan, United States • Minneapolis, Minnesota, United States +24 more locations

Not Yet RecruitingNA784 miles

Weight Bearing After Pelvis and Acetabulum Fracture Fixation

NCT07189156

The goal of this study to determine if a randomized clinical trial of immediate versus delayed weight bearing after undergoing surgical fixation of a pelvis or acetabulum fracture is feasible. The main questions it aims to answer are: Are surgeons willing to allow inclusion of their patients into such a trial? Are patients willing to participate in such a trial? Will patients be compliant with assigned weight bearing status in such a trial? Can good patient follow-up be obtained in such a trial? Is participation in such a trial safe? Patients from 7 medical centers will be enrolled, and randomized to immediate weight bearing as tolerated (WBAT) versus delayed WBAT (for 6-12 weeks). Feasibility metrics revolving around enrollment, follow-up, and documentation will be monitored, as well as medical and surgical complications. This pilot study will help inform feasibility and design of a larger definitive multicenter randomized controlled trial (RCT) on this topic.

Pelvis FracturesAcetabulum Fractures

University of Mississippi Medical Center200 participantsStarted Oct 2025

Birmingham, Alabama, United States • Colton, California, United States • Indianapolis, Indiana, United States +4 more locations

Active Not Recruiting795 miles

Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative

NCT03910933

Effective patient education improves health literacy and engagement thus improving long-term health outcomes. Health literacy is imperative to make informed health decisions and relies on the ability to obtain, process and understand health information; and is the cornerstone of safe health management. It is necessary to evaluate educational initiatives to determine their effectiveness in knowledge translation. A more effective way to provide patient education is to utilize media technology. Current education styles do not teach patients in the best way as they are not consistent with how people of all ages currently learn (through technology). In addition, patient teaching most commonly occurs during highly stressful times like hospital visits with new diagnoses. Current patient educational methods are costly given the amount of health provider time required. Electronic KITE teaching modules are infographic visual representations that present information quickly and clearly, integrating words and graphics to tell a story to reveal information. Infographic presentations are tools which facilitate self-directed learning with understandable, accessible information presented in an engaging way with an aim to enhance learning for children and their families. Patients are able to learn at a pace consistent with their learning style to facilitate knowledge development and health literacy.

Health LiteracyAnticoagulation

University of Alberta248 participantsStarted Jun 2017

Chicago, Illinois, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +3 more locations

COMPLETEDPhase 3830 miles

Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

NCT00371033

The purpose of this study is to determine whether pregabalin is an effective treatment for Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)324 participantsStarted Mar 2006

Los Angeles, California, United States • Los Angeles, California, United States • Stanford, California, United States +8 more locations

RECRUITINGPhase 1833 miles

R-2487 in Patients With Rheumatoid Arthritis

NCT05961592

The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.

Arthritis, Rheumatoid

Rise Therapeutics LLC73 participantsStarted Oct 2023

San Diego, California, United States • Doral, Florida, United States • Miami, Florida, United States +2 more locations

Active Not RecruitingPhase 2833 miles

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

NCT06101329

The goal of this clinical study is to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for prevention of HIV in the cisgender women in the US. The primary objectives of this study are: 1) to characterize the pharmacokinetics (PK) of LEN in United States (US) cisgender women; 2) to evaluate the safety of LEN and F/TDF for pre-exposure prophylaxis (PrEP) in US cisgender women; and 3) to evaluate the general acceptability of LEN injections and oral F/TDF in US cisgender women.

Pre-Exposure Prophylaxis of HIV Infection

Gilead Sciences253 participantsStarted Nov 2023

Birmingham, Alabama, United States • San Diego, California, United States • Washington D.C., District of Columbia, United States +8 more locations

RECRUITINGNA879 miles

Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

NCT04883671

The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: * Stereotactic Body Radiation Therapy (SBRT)

Adenoid Cystic CarcinomaMetastatic Adenoid Cystic Carcinoma

Dana-Farber Cancer Institute32 participantsStarted Dec 2021

San Francisco, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +2 more locations

RECRUITINGNA1020 miles

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

NCT06880835

This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.

Diabetes Mellitus, Type 1

Jaeb Center for Health Research30 participantsStarted Jun 2025

Louisville, Kentucky, United States • Philadelphia, Pennsylvania, United States • Seattle, Washington, United States

PreviousPage 164 of 781Next

Heart Diseasein Denver